Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2013, Article ID 724360, 12 pages
http://dx.doi.org/10.1155/2013/724360
Review Article

Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells

Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon

Received 29 April 2013; Accepted 13 June 2013

Academic Editor: Shaoguang Li

Copyright © 2013 Ahmad Hamad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. C. Nowell and D. A. Hungerford, “Chromosome studies on normal and leukemic human leukocytes,” Journal of the National Cancer Institute, vol. 25, pp. 85–109, 1960. View at Google Scholar · View at Scopus
  2. J. D. Rowley, “A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining,” Nature, vol. 243, no. 5405, pp. 290–293, 1973. View at Google Scholar · View at Scopus
  3. J. M. Goldman, “Chronic myeloid leukemia: a historical perspective,” Seminars in Hematology, vol. 47, no. 4, pp. 302–311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Chen, C. Peng, D. Li, and S. Li, “Molecular and cellular bases of chronic myeloid leukemia,” Protein and Cell, vol. 1, no. 2, pp. 124–132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Rohrbacher and J. Hasford, “Epidemiology of chronic myeloid leukaemia (CML),” Best Practice and Research, vol. 22, no. 3, pp. 295–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Calabretta and D. Perrotti, “The biology of CML blast crisis,” Blood, vol. 103, no. 11, pp. 4010–4022, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C. H. M. Jamieson, L. E. Ailles, S. J. Dylla et al., “Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML,” New England Journal of Medicine, vol. 351, no. 7, pp. 657–667, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. Report of the Medical Research Council's working party for therapeutic trials in leukemia, “Chronic granulocytic leukemia: comparison of radiotherapy and busulphan therapy,” British Medical Journal, vol. 1, pp. 201–208, 1968. View at Google Scholar
  9. S. G. O'Brien, F. Guilhot, R. A. Larson et al., “Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia,” New England Journal of Medicine, vol. 348, no. 11, pp. 994–1004, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Nasr and A. Bazarbachi, “Chronic myeloid leukemia: “archetype” of the impact of targeted therapies,” Pathologie Biologie, vol. 60, no. 4, pp. 239–245, 2012. View at Google Scholar
  11. M. Baccarani, J. Cortes, F. Pane et al., “Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 6041–6051, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. B. J. Druker, S. Tamura, E. Buchdunger et al., “Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells,” Nature Medicine, vol. 2, no. 5, pp. 561–566, 1996. View at Google Scholar · View at Scopus
  13. M. H. Cohen, G. Williams, J. R. Johnson et al., “Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia,” Clinical Cancer Research, vol. 8, no. 5, pp. 935–942, 2002. View at Google Scholar · View at Scopus
  14. T. P. Hughes, A. Hochhaus, S. Branford et al., “Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS),” Blood, vol. 116, no. 19, pp. 3758–3765, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Goldman, “How I treat chronic myeloid leukemia in the imatinib era,” Blood, vol. 110, no. 8, pp. 2828–2837, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Castagnetti, F. Palandri, M. Amabile et al., “Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party,” Blood, vol. 113, no. 15, pp. 3428–3434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Assouline and J. H. Lipton, “Monitoring response and resistance to treatment in chronic myeloid leukemia,” Current Oncology, vol. 18, no. 2, pp. e71–e83, 2011. View at Google Scholar · View at Scopus
  18. C. Preudhomme, J. Guilhot, F. E. Nicolini et al., “Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia,” New England Journal of Medicine, vol. 363, no. 26, pp. 2511–2521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Kantarjian, N. P. Shah, A. Hochhaus et al., “Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia,” New England Journal of Medicine, vol. 362, no. 24, pp. 2260–2270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Saglio, D.-W. Kim, S. Issaragrisil et al., “Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia,” New England Journal of Medicine, vol. 362, no. 24, pp. 2251–2259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. E. Cortes, D. Kim, H. M. Kantarjian et al., “Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial,” Journal of Clinical Oncology, vol. 30, no. 28, pp. 3486–3492, 2012. View at Google Scholar
  22. M. C. Müller, J. E. Cortes, D.-W. Kim et al., “Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations,” Blood, vol. 114, no. 24, pp. 4944–4953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. G. Brixey and R. W. Light, “Pleural effusions due to dasatinib,” Current Opinion in Pulmonary Medicine, vol. 16, no. 4, pp. 351–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Jabbour, J. E. Cortes, and H. M. Kantarjian, “Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?” Mayo Clinic Proceedings, vol. 84, no. 2, pp. 161–169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Rosti, F. Palandri, F. Castagnetti et al., “Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia,” Blood, vol. 114, no. 24, pp. 4933–4938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Ray, S. W. Cowan-Jacob, P. W. Manley, J. Mestan, and J. D. Griffin, “Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study,” Blood, vol. 109, no. 11, pp. 5011–5015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Puttini, A. M. L. Coluccia, F. Boschelli et al., “In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells,” Cancer Research, vol. 66, no. 23, pp. 11314–11322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Keller-V Amsberg and T. H. Brümmendorf, “Novel aspects of therapy with the dual src and abl kinase inhibitor bosutinib in chronic myeloid leukemia,” Expert Review of Anticancer Therapy, vol. 12, no. 9, pp. 1121–1127, 2012. View at Google Scholar
  29. J. Cortes, J. M. Goldman, and T. Hughes, “Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure,” Journal of the National Comprehensive Cancer Network, vol. 10, supplement 3, pp. S1–S13, 2012. View at Google Scholar
  30. M. Ohanian, J. Cortes, H. Kantarjian, and E. Jabbour, “Tyrosine kinase inhibitors in acute and chronic leukemias,” Expert Opinion on Pharmacotherapy, vol. 13, no. 7, pp. 927–938, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. T. O'Hare, W. C. Shakespeare, X. Zhu et al., “AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance,” Cancer Cell, vol. 16, no. 5, pp. 401–412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. F. P. S. Santos, H. Kantarjian, A. Quintás-Cardama, and J. Cortes, “Evolution of therapies for chronic myelogenous leukemia,” Cancer Journal, vol. 17, no. 6, pp. 465–476, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. T. O’Hare, M. Zabriskie, A. Eiring et al., “Pushing the limits to targeted therapy in chronic myeloid leukemia,” Nature Reviews, vol. 12, no. 8, pp. 513–526, 2012. View at Google Scholar
  34. J. E. Cortes, D. Kim -W, J. Pinilla-Ibarz et al., “PACE: a pivotal phase 2 trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation,” in Proceedings of the 17th Congress of the European Hematology Association, Amsterdam, The Netherlands, 2012.
  35. J. E. Cortes, H. Kantarjian, N. P. Shah et al., “Ponatinib in refractory philadelphia Chromosome-Positive leukemias,” New England Journal of Medicine, vol. 367, no. 22, pp. 2075–2088, 2012. View at Google Scholar
  36. M. E. Gorre, M. Mohammed, K. Ellwood et al., “Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification,” Science, vol. 293, no. 5531, pp. 876–880, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Hochhaus, S. Kreil, A. S. Corbin et al., “Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy,” Leukemia, vol. 16, no. 11, pp. 2190–2196, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. S. G. Willis, T. Lange, S. Demehri et al., “High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy,” Blood, vol. 106, no. 6, pp. 2128–2137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. T. O'Hare, C. A. Eide, and M. W. N. Deininger, “Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia,” Blood, vol. 110, no. 7, pp. 2242–2249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Bixby and M. Talpaz, “Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance,” ASH Education Program Book, no. 1, pp. 461–476, 2009. View at Google Scholar · View at Scopus
  41. G. Nestal de Moraes and P. S. Souza, “The interface between BCR-ABL-dependent and iIndependent resistance signaling pathways in chronic myeloid leukemia,” Leukemia Research and Treatment, vol. 2012, Article ID 671702, 19 pages, 2012. View at Publisher · View at Google Scholar
  42. A. S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. W. Deininger, and B. J. Druker, “Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity,” Journal of Clinical Investigation, vol. 121, no. 1, pp. 396–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Nicholson and T. Holyoake, “The chronic myeloid leukemia stem cell,” Clinical Lymphoma & Myeloma, vol. 9, pp. 376–381, 2009. View at Google Scholar · View at Scopus
  44. S. M. Graham, H. G. Jørgensen, E. Allan et al., “Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro,” Blood, vol. 99, no. 1, pp. 319–325, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Chen, C. Peng, C. Sullivan, D. Li, and S. Li, “Critical molecular pathways in cancer stem cells of chronic myeloid leukemia,” Leukemia, vol. 24, no. 9, pp. 1545–1554, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Copland, A. Hamilton, L. J. Elrick et al., “Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction,” Blood, vol. 107, no. 11, pp. 4532–4539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Wisniewski, M. Affer, J. Willshire, and B. Clarkson, “Further phenotypic characterization of the primitive lineage− CD34+CD38−CD90+CD45RA− hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia,” Blood Cancer Journal, vol. 1, no. 9, article e36, 2011. View at Google Scholar
  48. J. M. Goldman, “Chronic myeloid leukemia stem cells: now on the run,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 313–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Zhang and S. Li, “Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells,” Protein Cell, vol. 4, no. 3, pp. 186–196, 2013. View at Google Scholar
  50. O. Rådmark and B. Samuelsson, “Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis,” Biochemical and Biophysical Research Communications, vol. 396, no. 1, pp. 105–110, 2010. View at Google Scholar
  51. Y. Chen, Y. Hu, H. Zhang, C. Peng, and S. Li, “Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia,” Nature Genetics, vol. 41, no. 7, pp. 783–792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Zhang, H. Li, N. Ho, D. Li, and S. Li, “Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia,” Molecular and Cellular Biology, vol. 32, no. 10, pp. 1776–1787, 2012. View at Google Scholar
  53. K. Naka, T. Hoshii, T. Muraguchi et al., “TGF-Β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia,” Nature, vol. 463, no. 7281, pp. 676–680, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. Jagani, K. Song, J. L. Kutok et al., “Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors,” Cancer Research, vol. 69, no. 16, pp. 6546–6555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Hurtz, K. Hatzi, L. Cerchietti et al., “BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia,” Journal of Experimental Medicine, vol. 208, no. 11, pp. 2163–2174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. X. Wang, J. Zeng, M. Shi et al., “Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth,” DNA and Cell Biology, vol. 30, no. 2, pp. 71–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. O. Hantschel, W. Warsch, E. Eckelhart et al., “BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia,” Nature Chemical Biology, vol. 8, no. 3, pp. 285–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Walz, W. Ahmed, K. Lazarides et al., “Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice,” Blood, vol. 119, no. 15, pp. 3550–3560, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Samanta, B. Perazzona, S. Chakraborty et al., “Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia,” Leukemia, vol. 25, no. 3, pp. 463–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. A. K. Samanta, H. Lin, T. Sun, H. Kantarjian, and R. B. Arlinghaus, “Janus kinase 2: a critical target in chronic myelogenous leukemia,” Cancer Research, vol. 66, no. 13, pp. 6468–6472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Gupta, A. Verma, A. K. Mishra et al., “The Wnt pathway: emerging anticancer strategies,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 7, no. 2, pp. 138–147, 2013. View at Google Scholar
  62. H. H. Luu, R. Zhang, R. C. Haydon et al., “Wnt/β-catenin signaling pathway as novel cancer drug targets,” Current Cancer Drug Targets, vol. 4, no. 8, pp. 653–671, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Schürch, C. Riether, M. S. Matter, A. Tzankov, and A. F. Ochsenbein, “CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression,” Journal of Clinical Investigation, vol. 122, no. 2, pp. 624–638, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Zhao, J. Blum, A. Chen et al., “Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo,” Cancer Cell, vol. 12, no. 6, pp. 528–541, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Zhao, A. Chen, C. H. Jamieson et al., “Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia,” Nature, vol. 458, no. 7239, pp. 776–779, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Hu, Y. Chen, L. Douglas, and S. Li, “β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia,” Leukemia, vol. 23, no. 1, pp. 109–116, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Fereshteh, T. Ito, J. J. Kovacs et al., “ß-Arrestin2 mediates the initiation and progression of myeloid leukemia,” Proceedings of the National Academy of Sciences, vol. 109, no. 31, pp. 12532–12537, 2012. View at Google Scholar
  68. G. V. Helgason, M. Karvela, and T. L. Holyoake, “Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML,” Blood, vol. 118, no. 8, pp. 2035–2043, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Yu, L. Yang, M. Zhao et al., “Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells,” Leukemia, vol. 26, no. 8, pp. 1752–1760, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Calabretta and P. Salomoni, “Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors,” Leukemia and Lymphoma, vol. 52, no. 1, pp. 54–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Bellodi, M. R. Lidonnici, A. Hamilton et al., “Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells,” Journal of Clinical Investigation, vol. 119, no. 5, pp. 1109–1123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. B. G. Mar, D. Amakye, I. Aifantis, and S. Buonamici, “The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis,” Leukemia, vol. 25, no. 11, pp. 1665–1673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. W. Su, F. Meng, L. Huang, M. Zheng, W. Liu, and H. Sun, “Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling,” Experimental Hematology, vol. 40, no. 5, pp. 418–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. Z. Jagani, M. Dorsch, and M. Warmuth, “Hedgehog pathway activation in chronic myeloid leukemia: a promise for a novel combination therapeutic approach?” Cell Cycle, vol. 9, no. 17, pp. 3449–3456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Dierks, R. Beigi, G.-R. Guo et al., “Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation,” Cancer Cell, vol. 14, no. 3, pp. 238–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. H.-F. Liao, Y.-C. Su, Z.-Y. Zheng et al., “Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells,” Biomedicine and Pharmacotherapy, vol. 66, no. 5, pp. 378–383, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Long, H. Zhu, C. Zhu, T. Liu, and W. Meng, “Activation of the hedgehog pathway in chronic myelogeneous leukemia patients,” Journal of Experimental and Clinical Cancer Research, vol. 30, no. 1, article 8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Babashah, M. Sadeghizadeh, A. Hajifathali et al., “Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells,” International Journal of Cancer, vol. 133, no. 3, pp. 579–589, 2013. View at Google Scholar
  79. H. Yuan, Z. Wang, L. Li et al., “Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis,” Blood, vol. 119, no. 8, pp. 1904–1914, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Li, L. Wang, L. Li et al., “Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib,” Cancer Cell, vol. 21, no. 2, pp. 266–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Ito, R. Bernardi, A. Morotti et al., “PML targeting eradicates quiescent leukaemia-initiating cells,” Nature, vol. 453, no. 7198, pp. 1072–1078, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. M. A. G. Essers, S. Offner, W. E. Blanco-Bose et al., “IFNα activates dormant haematopoietic stem cells in vivo,” Nature, vol. 458, no. 7240, pp. 904–908, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. F.-X. Mahon, D. Réa, J. Guilhot et al., “Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial,” The Lancet Oncology, vol. 11, no. 11, pp. 1029–1035, 2010. View at Publisher · View at Google Scholar · View at Scopus